|Bid||6.92 x 500|
|Ask||6.94 x 900|
|Day's Range||6.85 - 7.16|
|52 Week Range||4.60 - 7.16|
|PE Ratio (TTM)||-85.68|
|Earnings Date||Jun 1, 2017 - Jun 5, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||6.00|
BEIJING, Sept. 25, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA), a leading provider of vaccines in China, announced today preliminary top-line data from its Phase III clinical trial assessing the efficacy, immunogenicity and safety of the Company's proprietary Varicella vaccine against Chickenpox. The primary objective of the study was to evaluate the efficacy of the Varicella vaccine in the prevention of Chickenpox caused by Varicella-Zoster Virus (VZV). The preliminary Phase III data showed that Sinovac's Varicella vaccine was 87.1% (95% CI: 69.7%, 94.5%) efficacious against Chickenpox caused by VZV.
If you are a shareholder in Sinovac Biotech Ltd’s (NASDAQ:SVA), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Sinovac Biotech Ltd.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)